Drug Profile
Research programme: melanotransferrin conjugated therapeutics - biOasis Technologies
Alternative Names: BT-2111; BT-2211; Herceptin®-BT2111; MTf-I2S; MTf-TZM; MTfp-I2S; MTfp-miRNA; MTfp-siRNA; MTfp-TZM; Transcend-TrastuzumabLatest Information Update: 17 Aug 2021
Price :
$50
*
At a glance
- Originator biOasis Technologies; University of British Columbia
- Developer biOasis Technologies
- Class Drug conjugates; Enzymes; Immunoconjugates; Metalloproteins; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors; Enzyme replacements; ERBB 2 receptor antagonists; Gene silencing; Immunomodulators; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Lysosomal storage diseases; Mucopolysaccharidosis II
- No development reported Alzheimer's disease; Brain disorders; Breast cancer; Gangliosidoses; Glioblastoma
Most Recent Events
- 09 Aug 2021 Preclinical development in Lysosomal storage diseases is ongoing in USA (IV)
- 09 Aug 2021 Preclinical development in Mucopolysaccharidosis II is ongoing in USA (IV)
- 09 Aug 2021 biOasis Technologies receives patent allowance for xB3-fusion proteins comprising of iduronate-2-sulfatase in Japan